BREAST CANCER

There are several trials with oral SERDs in clinical development for hormone-receptor-positive metastatic breast cancer as both monotherapies and in combination therapy.

In an interview with Targeted Oncology, Lajos Pusztai, MD, DPhil, discussed the updated findings of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in patients with TNBC vs placebo plus chemotherapy.

An expert in breast cancer considers the role of intravenous and fixed-dose subcutaneous formulations of trastuzumab/pertuzumab as studied in the FeDeriCa and PHranceSCa clinical trials.

Chau T. Dang, MD, considers the case of a patient with early-stage HER2+ BC and discusses risk assessment and factors to consider when selecting between neoadjuvant and adjuvant treatment.

The use of endocrine therapy as single agents serves as the control arm for many clinical studies seeking to improve upon outcomes with combination regimens and newer agents for patients with HR-positive, HER2-negative advanced breast cancer.

Praluzatamab ravtansine achieved confirmed overall response rate in patients with advanced hormone receptor–positive, HER2-negative breast cancer, meeting the primary end point of the phase 2 CTMX-2009-002 trial.

Neil Vasan, MD, PhD, discusses how past studies have supported de-escalated approaches and other improvements to treatment for patients with HER2-positive breast cancer.

Before closing out their discussion on HER2+ breast cancer, expert oncologists share excitement for emerging treatment strategies and ongoing clinical trials.

Tiffany A. Traina, MD, discussed the ASCENT Trial examining patients with triple negative breast cancer.

A broad review of CNS-related clinical trial data in the setting of HER2+ breast cancer and concurrent brain metastases.

A brief discussion on treatment options available for patients with HER2+ metastatic breast cancer and brain metastases who progress on the HER2CLIMB regimen.

William J. Gradishar, MD, discusses the impact of new data on the National Comprehensive Cancer Network guidelines for patients with early-stage breast cancer.

Developers of elacestrant are seeking FDA approval of the agent for the treatment of patients with ER-positive/HER2-negative advanced or metastatic breast cancer.

Updated data from the CHiRP study demonstrates clinical potential with the RaDaR minimal residual disease test in patients with high-risk hormone receptor–positive human epidermal growth factor receptor 2-negative breast cancer.

Centering discussion on a patient case of HER2+ breast cancer with brain metastases, experts consider optimal treatment regimens in this setting.

Focusing on the HER2CLIMB regimen, experts consider appropriate treatment options for patients with HER2+ metastatic breast cancer in the third-line setting and beyond.

During a Targeted Oncology case-based roundtable event, Ruta D. Rao, MD, discussed the case of a patient with metastatic triple-negative breast cancer who progressed following frontline adjuvant ddAC-paclitaxel.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the key takeaways of the updated safety analysis of the DESTINY-Breast03 trial.

The ASCO’s expert panel released updated recommendations of pembrolizumab in combination with neoadjuvant chemotherapy for patients with stage II or stage III early triple-negative breast cancer

Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.

Expert oncologists share brief notes on their real-world experience managing HER2+ metastatic breast cancer with trastuzumab deruxtecan.

Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.

Neil Vasan, MD, PhD, discusses how the results of the TRAIN-2 trial impacted the treatment of patients with HER2-positive breast cancer.

Patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib had comparable overall survival outcomes to those given the standard dose.

Results of the phase 1 ELAINEI trial will inform the activity of single-agent lasofoxifene in estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations.